Compare Johnson & Johnson (JNJ) vs Charles Schwab Corporation Common Stock (SCHW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Charles Schwab Corporation Common Stock — how do they compare? Johnson & Johnson trades at $249.3 (market cap $598.96B), while Charles Schwab Corporation Common Stock trades at $102.37 (market cap $178.33B). The key difference: Johnson & Johnson is far larger — about 3.4× Charles Schwab Corporation Common Stock's market cap, and Johnson & Johnson pays the higher dividend (2.15%). Which is the better fit depends on your goals.
| JNJ | SCHW | |
|---|---|---|
Market Cap | $598.96B | $178.33B |
Volume | 6,156,228 | — |
Sector | Health | Financials |
52-Week High | $267.24 | $107.21 |
52-Week Low | $164.36 | $85.35 |
Enterprise Value | $631.90B | — |
Dividend Yield | 2.15% | 1.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
Charles Schwab (SCHW) trades at $102.01, up 0.44% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with Q1 2026 EPS beating expectations at $1.43 and revenue growth accelerating to $23.92 billion in 2025. Analyst sentiment remains positive with 58% buy ratings and a $120 consensus price target representing 18% upside potential. Recent news highlights strong trading activity and earnings optimism ahead of Q2 results.
The outlook remains favorable with earnings momentum and operational strength driving potential upside. Key opportunities include continued trading revenue growth and margin expansion, while risks involve interest rate sensitivity and market volatility. The stock's current valuation at 20.19 P/E appears reasonable given the company's profitability and growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →
